Home › Funds › 683 Capital Management, LLC › PHAT
683 Capital Management, LLC position in PHAT
Phathom Pharmaceuticals, Inc. · Health Care
683 Capital Management, LLC reported holding 1,850,000 shares of PHAT (Phathom Pharmaceuticals, Inc.) in its Q2 2026 13F filing — a position valued at US$20.1M, representing 1.07% of its reported portfolio and ranking #22 among its reported holdings. 683 Capital Management, LLC has disclosed PHAT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How 683 Capital Management, LLC's PHAT position evolved
683 Capital Management, LLC first disclosed a stake in PHAT in Q3 2023 at 1,100,000 shares (US$11.4M). The position peaked in Q4 2025 at 1,785,000 shares, worth US$29.6M. Across 12 filings, 683 Capital Management, LLC increased the stake 6 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,850,000 shares valued at US$20.1M. Notable position changes include a 29% increase in Q1 2024 (shares fell 3% over the following quarter), a 41% increase in Q1 2025 (shares rose 53% over the following quarter), a 46% increase in Q2 2025 (shares rose 23% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.10M | $11.41M | New |
| Q4 2023 | 1.28M | $11.69M | Add |
| Q1 2024 | 1.65M | $17.52M | Add |
| Q2 2024 | 1.40M | $14.42M | Reduce |
| Q3 2024 | 1.01M | $18.26M | Reduce |
| Q4 2024 | 1.02M | $8.32M | Add |
| Q1 2025 | 1.45M | $9.06M | Add |
| Q2 2025 | 2.10M | $20.19M | Add |
| Q3 2025 | 1.82M | $21.43M | Reduce |
| Q4 2025 | 1.78M | $29.61M | Reduce |
| Q1 2026 | 1.85M | $20.55M | Add |
| Q2 2026 | 1.85M | $20.07M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PHAT and 13F data
PHAT (Phathom Pharmaceuticals, Inc.) is a Health Care company. 30 other funds we track also report a position in PHAT — the largest reported positions include Frazier Life Sciences Management, L.P. (US$135.3M), Medicxi Ventures Management (Jersey) Ltd (US$81.0M), Carlyle Group Inc. (US$37.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PHAT
- Frazier Life Sciences Management, L.P. 12.47M sh · $135.26M · Q2 2026
- Medicxi Ventures Management (Jersey) Ltd 7.46M sh · $80.99M · Q2 2026
- Carlyle Group Inc. 3.50M sh · $37.94M · Q2 2026
- NEA Management Company, LLC 1.96M sh · $21.27M · Q2 2026
- Catalys Pacific, LLC 1.88M sh · $13.74M · Q3 2026
- Propel Bio Management, LLC 1.05M sh · $11.40M · Q2 2026
- EcoR1 Capital, LLC 625.00K sh · $6.78M · Q2 2026
More on 683 Capital Management, LLC
FAQ
How long has 683 Capital Management, LLC held PHAT?
683 Capital Management, LLC has disclosed PHAT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is 683 Capital Management, LLC's current position in PHAT?
As of Q2 2026, 683 Capital Management, LLC holds 1.85M shares of PHAT (Phathom Pharmaceuticals, Inc.), valued at $20.07M, representing 1.07% of its reported portfolio and ranking #22.
Has 683 Capital Management, LLC been buying or selling PHAT?
In the latest 13F filing (Q2 2026), 683 Capital Management, LLC held unchanged its position in PHAT. The position peaked in Q4 2025 at 1.78M shares.
Which other funds hold PHAT?
Other major institutional holders of PHAT include Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, Carlyle Group Inc., among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.